Proteasome inhibitor bortezomib enhances the effect of standard chemotherapy in small cell lung cancer

Small cell lung cancer (SCLC) is an aggressive cancer showing a very poor prognosis because of metastasis formation at an early stage and acquisition of chemoresistance. One key driver of chemoresistance is the transcription factor Forkhead box protein M1 (FOXM1) that regulates cell cycle proliferat...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Taromi, Sanaz, Lewens, Florentine, Arsenic, Ruza, Sedding, Dagmar, Sänger, Jörg, Kunze, Almut, Möbs, Markus, Benecke, Joana, Freitag, Helma, Christen, Friederike, Kaemmerer, Daniel, Lupp, Amelie, Heilmann, Mareike, Lammert, Hedwig, Schneider, Claus-Peter, Richter, Karen, Hummel, Michael, Siegmund, Britta, Burger, Meike, Briest, Franziska, Grabowski, Patricia
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2017
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5722545/
https://ncbi.nlm.nih.gov/pubmed/29228593
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.21221
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados